IRIS
GREMESE, ELISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 446
AS - Asia 198
EU - Europa 156
AF - Africa 7
SA - Sud America 5
Totale 812
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 443
SG - Singapore 148
CN - Cina 40
FI - Finlandia 38
CZ - Repubblica Ceca 31
IE - Irlanda 31
DE - Germania 14
FR - Francia 12
GB - Regno Unito 7
NG - Nigeria 7
IT - Italia 6
SE - Svezia 5
IN - India 4
NL - Olanda 4
RU - Federazione Russa 3
AT - Austria 2
BE - Belgio 2
BR - Brasile 2
CA - Canada 2
CL - Cile 2
IL - Israele 2
AM - Armenia 1
AR - Argentina 1
JP - Giappone 1
KR - Corea 1
PA - Panama 1
RO - Romania 1
TH - Thailandia 1
Totale 812
Salva come PNG Salva come JPEG
Città #
Chandler 117
Singapore 99
Boardman 70
Helsinki 38
Shanghai 37
Dublin 31
Wilmington 28
Ashburn 26
New York 20
Brno 19
Lawrence 13
Princeton 13
Olomouc 12
Paris 11
San Mateo 10
Benin City 7
London 7
Ann Arbor 5
Collegeville 5
Leawood 5
Woodbridge 5
Amsterdam 4
Los Angeles 4
Munich 4
Pune 4
Redwood City 4
Sassari 4
Phoenix 3
Santa Clara 3
Tukwila 3
Brussels 2
Campinas 2
Fairfield 2
Scandicci 2
Shenzhen 2
Toronto 2
Bangkok 1
Cambridge 1
Falkenstein 1
Forest City 1
Las Vegas 1
Monmouth Junction 1
Moscow 1
Nanjing 1
Nuremberg 1
Panama City 1
Río Cuarto 1
Seattle 1
Tel Aviv 1
Tokyo 1
Vienna 1
Yerevan 1
Totale 639
Salva come PNG Salva come JPEG
Nome #
Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis. 45
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial 44
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 43
Anti-LL37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsA. 43
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 34
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study 33
Allele *2 of the HS1,2A enhancer of the Ig regulatory region associates with rheumatoid arthritis 28
Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study 27
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 27
B cell depletion and a T cell-targeted therapy allows to control the sudden onset of diabetes and lupus, without steroids 27
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: an IG-IBD study 26
Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report 23
Synovial B cells of rheumatoid arthritis express ZAP-70 which increases the survival and correlates with the inflammatory and autoimmune phenotype 22
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 20
Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study 19
Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results 19
IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy 17
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real???Life Setting 15
Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis 10
EFFECTIVENESS AND SAFETY OF BELIMUMAB IN PATIENTSWITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM A LARGE, NATIONWIDE, MULTICENTRIC STUDY 9
Spondiloartriti sieronegative 9
Artrite Reumatoide 8
Comment on: Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease 8
Measuring the T-cell down-regulation of TCR-zeta, ZAP-70 and CD28 in arthritis patients: An old tool for new biomarkers 8
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study-Joint and Skin (BeRLiSS-JS) 7
Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis 7
Circulating Human Collagen II-Reactive T Cell in Early Rheumatoid Arthritis Produce IL17. 6
Artrite reumatoide 6
Persistence, effectiveness and safety of ustekinumab compared to TNF inhibitors in psoriatic arthritis within the Italian PsABio cohort 6
Lupus eritematoso sistemico 6
Rheumatologic Symptoms in Patients with Mixed Cryoglobulinemia 6
Synovial fluid-derived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis 6
Adult onset Still's disease and pregnancy 5
Metabolic syndrome in autoimmune diseases: prevalence and relationship with the inflammatory burden 5
An unusual lung involvement in scleroderma: lipoid pneumonia 5
Metabolic syndrome, QTC interval lengthening and inflammation in rheumatoid arthritis. Analysis of their respective role 5
Early Spondyloarthritis Clinic: Organizational Improvements in the Patient Journey 5
Analysis of response to infliximab in ankylosing spondylitis (AS) according to the axial and/or peripheral involvement. autoantibodies and drop outs are more frequent in the peripheral subset 4
The role of High-mobility group box protein 1 in collagen antibody-induced arthritis is dependent on Vascular endothelial growth factor 4
Antineutrophil cytoplasmic autoantibodies (ANCA) positivity as a red flag of severe disease in lupus nephritis 4
Biological therapies in autoimmune chronic inflammatory diseases (ACIDs) 4
B-cell directed therapy in rheumatoid arthritis: predictive factors of efficacy and assessment of regeneration profile 4
Long-term anti-TNF therapy and risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison among adalimumab, etanercept and infliximab 4
Off-label use of rituximab for SLE in Europe: a comparison to patients treated with conventional immunosuppressive medications 3
The UltraSound-CLinical ARthritis Activity (US-CLARA) index: Properties of a new composite disease activity index for rheumatoid arthritis 3
Minimal disease activity in early and longstanding rheumatoid arthritis 3
Amplifying the concept of psoriatic arthritis: The role of autoimmunity in systemic psoriatic disease 3
Gene-gene interaction and early rheumatoid arthritis: effects on the response to therapy 3
The prognostic significance of the Birmingham Vasculitis Activity Score (BVAS) with systemic vasculitis patients transferred to the intensive care unit (ICU) 3
Gastrointestinal involvement in systemic vasculitis 3
Peripheral blood B cells subsets in patients with systemic lupus erythematosus: correlation with disease activity and organ involvement 3
Disease-modifying Antirheumatic Drugs (DMARD) and Combination Therapy of Conventional DMARD in Patients with Spondyloarthritis and Psoriatic Arthritis with Axial Involvement 3
[Class IV-G and IV-S lupus nephritis, interstitial infiltrates and prognosis: state of the art and unmet medical needs] 3
Case report: Dupilumab treatment improved type 2 disorders in a patient with IPEX syndrome diagnosis 3
Access of arthritis patients to an early arthritis clinic in three different settings: the very early ra represents the best clinical and therapeutic opportunity to reach das remission. Quality indicators (QI) of the italian ministry of health program 3
Gender equality in Rheumatology 3
Hepatocyte growth factor (HGF)/transforming growth factor (TGF-BETA1) balance in renal biopsies and clinical outcome in patients with lupus nephritis treated with cyclophosphamide 3
Association of the 22 genotype of enhancer HS1,2A of the Ig heavy 3′ regulatory region with non response to DMARDS and response to rituximab in rheumatoid arthritis patients 3
The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk 3
Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group 3
ompassionate use of anti-IL6 receptor antibodies in critically ill patients with acute respiratory distress syndrome due to SARS-CoV-2 3
Microvascular heart involvement in systemic autoimmune diseases: The purinergic pathway and therapeutic insights from the biology of the diseases 3
Obesity as a risk and severity factor in rheumatic diseases (autoimmune chronic inflammatory diseases) 3
Metaflammation, PEDF and Chemerin: Potential Systemic Factors Which Link Obesity To Response To Therapy In Early Rheumatoid Arthritis. 3
Very early rheumatoid arthritis (VERA) is the best predictor of major outcomes: clinical remission and radiographic non-progression 3
A brief battery for the evaluation of cognitive deficits in italian SLE patients 3
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 3
ZAP70 B Cells and Plasmablasts As Markers of Disease Activity and Remission in Systemic LUPUS Erythematosus Nephritis 3
Very early rheumatoid arthritis is the major predictor of major outcome: clinical ACR remission and radiographic non-progression 3
A brief battery for the evaluation of cognitive deficits in italian SLE patients 3
ACPA–IL-6 as the best biomarkers to differentiate early rheumatoid arthritis from undifferentiated arthritis: analysis of the diagnostic performance 3
The Role of Microrna-34 and Microrna-22 in Dendritic Cells and Monocyte Activation in Rheumatoid Arthritis 3
Adult Onset Still's Disease and Radiotherapy treatment for breast cancer: Case report about management of this rare association and literature review. 3
Anti-nucleosome antibodies: correlations with activity and chronicity disease indexes in systemic lupus erythematosus patients with renal involvement 3
Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy 2
Analysis of the kinetic of expression of tristetraprolin and HuR by rheumatoid arthritis patients peripheral blood mononuclear cells stimulated with lipopolysaccharide 2
Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab 2
Integrin alpha2bbeta3 gene polymorphism and the microvascular system in scleroderma 2
No higher risk of respiratory symptoms in Italian rheumatological patients under IL-6R-inhibitor therapy in SARS-CoV-2 pandemic 2
The role of high-mobility group box protein 1 in collagen antibody-induced arthritis is dependent on vascular endothelial growth factor 2
Effects of l-Arginine Plus Vitamin C Supplementation on l-Arginine Metabolism in Adults with Long COVID: Secondary Analysis of a Randomized Clinical Trial 2
Should we consider tumor necrosis factor as the only target in spondyloarthritides? 2
Basophil activation and serum IL-5 levels as possible monitor biomarkers in severe eosinophilic asthma patients treated with anti-IL-5 drugs 2
Interleukin-6 and IgA-rheumatoid factor are crucial for baseline erosiveness, and anti-citrullinated peptide antibodies for radiographic progression in early rheumatoid arthritis treated according to a treat-to-target strategy 2
Antiphospholipid syndrome and preeclampsia 2
Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate: results of an open trial 2
An autosomal recessive DNASE1L3-related autoimmune disease with unusual clinical presentation mimicking systemic lupus erythematosus 2
A multiparametric risk table for loss of clinical remission status in patients with rheumatoid arthritis: A starter study post-hoc analysis 2
Long-term retention rate of anakinra in adult onset Still’s disease and predictive factors for treatment response 2
Is Citrullination Required for the Presence of Restricted Clonotypes Reacting With Type II Collagen? Comment on the Article by Chemin et al 2
The B side of rheumatoid arthritis pathogenesis 2
Checkpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs): tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestations 2
PTPN22 1858C>T polymorphism is a negative biomarker of (EULAR GOOD) response to methotrexate in a cohort of early rheumatoid arthritis 2
Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry 2
Polymorphisms of the IgH enhancer HS1.2 and risk of systemic lupus erythematosus 2
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo–Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors 2
Driving chronicity in rheumatoid arthritis: Perpetuating role of myeloid cells 2
Interleukin-1β and interleukin-6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritis 2
Malnutrition in COVID-19 survivors: prevalence and risk factors 2
The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts 2
Totale 808
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.779
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.779
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202 0 0 0 0 0 0 0 0 0 0 0 2
2020/202159 0 0 0 0 1 26 7 2 11 8 0 4
2021/202229 1 0 1 6 0 1 1 3 3 5 4 4
2022/2023277 28 13 28 43 21 25 0 27 45 30 16 1
2023/2024730 11 13 54 15 1 32 18 9 5 7 19 546
2024/20253 3 0 0 0 0 0 0 0 0 0 0 0
Totale 1.100